10-Q

PART I – FINANCIAL INFORMATION

Item 1. Interim Condensed Consolidated Financial Statements

Neogen Corporation

Condensed Consolidated Balance Sheets

(in thousands, except shares)


	February 28, 2025			May 31, 2024
Assets	(unaudited)
Current Assets
Cash and cash equivalents	$	127,705		$	170,611
Marketable securities		—			325
Accounts receivable, net of allowance of $5,305 and $4,140		160,068			173,005
Inventories
Raw materials		75,047			78,799
Work-in-process		14,305			10,990
Finished goods		136,250			111,839
		225,602			201,628
Less inventory reserve		(20,160	)		(12,361	)
Inventories, net		205,442			189,267
Prepaid expenses and other current assets		58,498			56,025
Total Current Assets		551,713			589,233
Net Property and Equipment		327,838			277,104
Other Assets
Right of use assets		17,314			14,785
Goodwill (note 5)		1,671,705			2,135,632
Intangible assets, net		1,439,237			1,511,653
Other non-current assets		28,529			20,426
Total Assets	$	4,036,336		$	4,548,833
Liabilities and Stockholders’ Equity
Current Liabilities
Current portion of finance lease	$	2,501		$	2,447
Accounts payable		72,240			83,061
Accrued compensation		18,335			19,949
Income tax payable		12,924			10,449
Accrued interest		3,438			10,985
Deferred revenue		5,769			4,632
Other current liabilities		25,993			22,800
Total Current Liabilities		141,200			154,323
Deferred Income Tax Liability		301,053			326,718
Non-Current Debt		890,605			888,391
Other Non-Current Liabilities		43,131			35,259
Total Liabilities		1,375,989			1,404,691
Commitments and Contingencies (note 8)
Equity
Preferred stock, $1.00 par value, 100,000 shares authorized, none issued and outstanding		-			-
Common stock, $0.16 par value, 315,000,000 shares authorized, 217,038,267 and 216,614,407 shares issued and outstanding		34,725			34,658
Additional paid-in capital		2,597,540			2,583,885
Accumulated other comprehensive loss		(47,690	)		(30,021	)
Retained earnings		75,772			555,620
Total Stockholders’ Equity		2,660,347			3,144,142
Total Liabilities and Stockholders’ Equity	$	4,036,336		$	4,548,833

The accompanying notes are an integral part of these condensed consolidated financial statements.

Neogen Corporation

Condensed Consolidated Statements of Operations (unaudited)

(in thousands, except shares)


	Three months ended February 28/29,						Nine months ended February 28/29,
	2025			2024			2025			2024
Revenues
Product revenues	$	196,488		$	202,178		$	596,555		$	610,448
Service revenues		24,492			26,634			72,647			76,980
Total Revenues		220,980			228,812			669,202			687,428
Cost of Revenues
Cost of product revenues		95,815			98,144			293,488			293,456
Cost of service revenues		14,900			13,785			47,193			43,554
Total Cost of Revenues		110,715			111,929			340,681			337,010
Gross Profit		110,265			116,883			328,521			350,418
Operating Expenses
Sales and marketing		44,595			47,920			136,939			138,535
General and administrative		55,782			52,087			165,224			148,929
Goodwill impairment		—			—			461,390			—
Research and development		4,473			4,853			14,780			17,331
Total Operating Expenses		104,850			104,860			778,333			304,795
Operating Income (Loss)		5,415			12,023			(449,812	)		45,623
Other Expense
Interest income		699			1,612			2,466			5,265
Interest expense		(17,737	)		(18,285	)		(54,493	)		(54,773	)
Other, net		1,896			(1,172	)		(69	)		(4,021	)
Total Other Expense		(15,142	)		(17,845	)		(52,096	)		(53,529	)
Loss Before Taxes		(9,727	)		(5,822	)		(501,908	)		(7,906	)
Income Tax Expense (Benefit)		1,230			(3,800	)		(22,060	)		(3,900	)
Net Loss	$	(10,957	)	$	(2,022	)	$	(479,848	)	$	(4,006	)
Net Loss Per Share
Basic	$	(0.05	)	$	(0.01	)	$	(2.21	)	$	(0.02	)
Diluted	$	(0.05	)	$	(0.01	)	$	(2.21	)	$	(0.02	)
Weighted Average Shares Outstanding
Basic		217,031,907			216,597,777			216,845,782			216,438,643
Diluted		217,031,907			216,597,777			216,845,782			216,438,643

The accompanying notes are an integral part of these condensed consolidated financial statements.

Neogen Corporation

Condensed Consolidated Statements of Comprehensive (Loss) Income (unaudited)

(in thousands)


	Three months ended February 28/29,						Nine months ended February 28/29,
	2025			2024			2025			2024
Net loss	$	(10,957	)	$	(2,022	)	$	(479,848	)	$	(4,006	)
Other comprehensive (loss) income
Foreign currency translation (loss) gain		(2,658	)		(4,561	)		(14,775	)		117
Unrealized gain on marketable securities (1)		—			77			—			917
Unrealized (loss) gain on derivative instruments (2)		(287	)		139			(2,894	)		2,744
Other comprehensive (loss) income, net of tax:		(2,945	)		(4,345	)		(17,669	)		3,778
Total comprehensive loss	$	(13,902	)	$	(6,367	)	$	(497,517	)	$	(228	)

(1) Amounts are net of tax of $24 and $290 during the three and nine months ended February 29, 2024, respectively.

(2) Amounts are net of tax of $(91) and $44 during the three months ended February 28, 2025 and February 29, 2024 and $(914) and $867 during the nine months ended February 28, 2025 and February 29, 2024, respectively.

The accompanying notes are an integral part of these condensed consolidated financial statements.

Neogen Corporation

Condensed Consolidated Statements of Equity (unaudited)

(in thousands, except shares)


					Additional		Accumulated Other
	Common Stock				Paid-in		Comprehensive			Retained
	Shares		Amount		Capital		Loss			Earnings			Total
May 31, 2024		216,614,407	$	34,658	$	2,583,885	$	(30,021	)	$	555,620		$	3,144,142
Exercise of options, RSUs and share-based compensation expense, net of taxes		4,854		1		4,017		—			—			4,018
Issuance of shares under employee stock purchase plan		78,877		13		1,028		—			—			1,041
Net loss		—		—		—		—			(12,609	)		(12,609	)
Other comprehensive loss		—		—		—		(1,400	)		—			(1,400	)
August 31, 2024		216,698,138	$	34,672	$	2,588,930	$	(31,421	)	$	543,011		$	3,135,192
Exercise of options, RSUs and share-based compensation expense, net of taxes		245,879		40		3,444		—			—			3,484
Net loss		—		—		—		—			(456,282	)		(456,282	)
Other comprehensive loss		—		—		—		(13,324	)		—			(13,324	)
November 30, 2024		216,944,017	$	34,712	$	2,592,374	$	(44,745	)	$	86,729		$	2,669,070
Exercise of options, RSUs and share-based compensation expense, net of taxes		15,478		—		4,121		—			—			4,121
Issuance of shares under employee stock purchase plan		78,772		13		1,045		—			—			1,058
Net loss		—		—		—		—			(10,957	)		(10,957	)
Other comprehensive loss		—		—		—		(2,945	)		—			(2,945	)
February 28, 2025		217,038,267	$	34,725	$	2,597,540	$	(47,690	)	$	75,772		$	2,660,347


							Accumulated
					Additional		Other
	Common Stock				Paid-in		Comprehensive			Retained
	Shares		Amount		Capital		Loss			Earnings			Total
May 31, 2023		216,245,501	$	34,599	$	2,567,828	$	(33,251	)	$	565,041		$	3,134,217
Exercise of options, RSUs and share-based compensation expense, net of taxes		2,591		—		2,661		—			—			2,661
Issuance of shares under employee stock purchase plan		62,490		11		1,028		—			—			1,039
Net income		—		—		—		—			1,503			1,503
Other comprehensive income		—		—		—		6,755			—			6,755
August 31, 2023		216,310,582	$	34,610	$	2,571,517	$	(26,496	)	$	566,544		$	3,146,175
Exercise of options, RSUs and share-based compensation expense, net of taxes		209,714		34		3,477		—			—			3,511
Net loss		—		—		—		—			(3,487	)		(3,487	)
Other comprehensive income		—		—		—		1,368			—			1,368
November 30, 2023		216,520,296	$	34,644	$	2,574,994	$	(25,128	)	$	563,057		$	3,147,567
Exercise of options, RSUs and share-based compensation expense, net of taxes		15,130		2		3,749		—			—			3,751
Issuance of shares under employee stock purchase plan		72,320		11		1,212		—			—			1,223
Net loss		—		—		—		—			(2,022	)		(2,022	)
Other comprehensive loss		—		—		—		(4,345	)		—			(4,345	)
February 29, 2024		216,607,746	$	34,657	$	2,579,955	$	(29,473	)	$	561,035		$	3,146,174

The accompanying notes are an integral part of these condensed consolidated financial statements.

Neogen Corporation

Condensed Consolidated Statements of Cash Flows (unaudited)

(in thousands)


	Nine months ended February 28/29,
	2025			2024
Cash Flows provided by Operating Activities
Net loss	$	(479,848	)	$	(4,006	)
Adjustments to reconcile net loss to net cash from operating activities:
Depreciation and amortization		89,222			87,853
Deferred income taxes		(33,113	)		98
Share-based compensation		12,961			9,829
Loss on disposal of property and equipment		99			762
Amortization of debt issuance costs		2,580			2,581
Goodwill and other asset impairment		470,832			—
Other		(290	)		(74	)
Change in operating assets and liabilities, net of business acquisitions:
Accounts receivable, net		9,133			(16,136	)
Inventories, net		(25,124	)		(48,663	)
Prepaid expenses and other current assets		(6,422	)		(25,170	)
Accounts payable and accrued liabilities		5,985			21,386
Interest expense accrual		(7,547	)		(7,711	)
Change in other non-current assets and non-current liabilities		3,234			(12,232	)
Net Cash provided by Operating Activities		41,702			8,517
Cash Flows used for Investing Activities
Purchases of property, equipment and other non-current intangible assets		(88,459	)		(87,167	)
Proceeds from the maturities of marketable securities		325			75,319
Proceeds from the sale of property and equipment and other		4,868			62
Net Cash used for Investing Activities		(83,266	)		(11,786	)
Cash Flows provided by Financing Activities
Exercise of stock options and issuance of employee stock purchase plan shares		2,242			2,443
Tax payments related to share-based awards		(1,479	)		(96	)
Repayment of finance lease and other		(248	)		(348	)
Net Cash provided by Financing Activities		515			1,999
Effects of Foreign Exchange Rate on Cash		(1,857	)		(533	)
Net Decrease in Cash and Cash Equivalents		(42,906	)		(1,803	)
Cash and Cash Equivalents, Beginning of Year		170,611			163,240
Cash and Cash Equivalents, End of Year	$	127,705		$	161,437
Supplemental cash flow information
Property and equipment obtained for noncash consideration	$	930		$	—
Right of use assets obtained in exchange for new operating lease liabilities	$	6,976		$	4,073

The accompanying notes are an integral part of these condensed consolidated financial statements.

NEOGEN CORPORATION

NOTES TO INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

(Dollar amounts in thousands except shares)

1. DESCRIPTION OF BUSINESS AND BASIS OF PRESENTATION

DESCRIPTION OF BUSINESS

Neogen Corporation and subsidiaries ("Neogen," "we," "our" or the "Company") develop, manufacture and market a diverse line of products and services dedicated to food and animal safety. Our Food Safety segment consists primarily of diagnostic test kits and complementary products (e.g., culture media) sold to food producers and processors to detect dangerous and/or unintended substances in human food and animal feed, such as foodborne pathogens, spoilage organisms, natural toxins, food allergens, genetic modifications, ruminant by-products, meat speciation, drug residues, pesticide residues and general sanitation concerns. The majority of the test kits are disposable, single-use, immunoassay and DNA detection products that rely on proprietary antibodies and RNA and DNA testing methodologies to produce rapid and accurate test results. Our expanding line of food safety products also includes genomics-based diagnostic technology, and advanced software systems that help testers objectively analyze and store, as well as perform analysis on, their results from multiple locations over extended periods.

Neogen’s Animal Safety segment is engaged in the development, manufacture, marketing and distribution of veterinary instruments, pharmaceuticals, vaccines, topicals, parasiticides, diagnostic products, cleaners, biosecurity products and genomics testing services for the worldwide animal safety market. The majority of these consumable products are marketed through veterinarians, retailers, livestock producers and animal health product distributors. Our line of drug detection products is sold worldwide for the detection of abused and therapeutic drugs in animals and animal products, and has expanded into the workplace and human forensic markets.

BASIS OF PRESENTATION AND CONSOLIDATION

The accompanying unaudited condensed consolidated financial statements include the accounts of Neogen and its wholly owned subsidiaries and have been prepared in accordance with accounting principles generally accepted in the United States of America (generally accepted accounting principles) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by generally accepted accounting principles for complete financial statements.

In our opinion, all adjustments considered necessary for a fair statement of the results of the interim period have been included in the accompanying unaudited condensed consolidated financial statements. All intercompany balances and transactions have been eliminated in consolidation. These unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and the notes thereto included in our Annual Report on Form 10-K for the fiscal year ended May 31, 2024.

New Accounting Pronouncements Not Yet Adopted

Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures

In November 2023, the FASB issued ASU 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures, which modifies the disclosure and presentation requirements of reportable segments. The amendments in the update require the disclosure of significant segment expenses that are regularly provided to the chief operating decision maker (CODM) and included within each reported measure of segment profit and loss. The amendments also require disclosure of all other segment items by reportable segment and a description of its composition. Additionally, the amendments require disclosure of the title and position of the CODM and an explanation of how the CODM uses the reported measure(s) of segment profit or loss in assessing segment performance and deciding how to allocate resources. This update is effective for annual periods beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024. Early adoption is permitted. We expect to adopt this guidance for our fiscal year 2025 annual reporting and are currently finalizing our assessment of the impact that this standard will have on our segment disclosures.

Income Taxes (Topic 740): Improvements to Income Tax Disclosures

In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures, which expands disclosures in an entity’s income tax rate reconciliation table and disclosures regarding cash taxes paid both in the U.S. and foreign jurisdictions. The update will be effective for annual periods beginning after December 15, 2024. This guidance becomes effective for our fiscal year 2026 annual reporting. The Company is currently evaluating the impact that this guidance will have on the presentation of its consolidated financial statements and accompanying notes.

Income Statement (Topic 220): Expense Disaggregation Disclosures

In November 2024, the FASB issued ASU No. 2024-03, Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures, which requires a public business entity to provide disaggregated disclosures, in the notes to the financial statements, of certain categories of expenses that are included in expense line items on the face of the income statement. The amendments in this Update are effective for annual reporting periods beginning after December 15, 2026, and interim reporting periods beginning after December 15, 2027. The Company is currently evaluating the impact that the new guidance will have on the presentation of its consolidated financial statements and accompanying notes.

2. REVENUE RECOGNITION

The Company derives revenue from two primary sources—product revenue and service revenue.

Product revenue consists of shipments of:

•

Diagnostic test kits, culture media and related products used by food producers and processors to detect harmful natural toxins, foodborne bacteria, allergens and levels of general sanitation;

•

Consumable products marketed to veterinarians, retailers, livestock producers and animal health product distributors; and

•

Biosecurity products to assist in the control of rodents, insects and disease in and around agricultural, food production and other facilities.

Revenues for our products are recognized and invoiced when the product is shipped to the customer.

Service revenue consists primarily of:

•

Genomic identification and related interpretive bioinformatic services;

•

Neogen Analytics; and

•

Other commercial laboratory services.

Revenues for Neogen’s genomics and commercial laboratory services are recognized and invoiced when the applicable laboratory service is performed and the results are conveyed to the customer. Revenues for Neogen Analytics is earned ratably over the term of the underlying agreement.

Payment terms for products and services are generally 30 to 90 days.

Contract liabilities represent deposits made by customers before the satisfaction of performance obligation(s) and recognition of revenue. Upon completion of the performance obligation(s) that the Company has with the customer, the liability for the customer deposit is relieved and revenue is recognized. These customer deposits are recorded within deferred revenue on the condensed consolidated balance sheets. Changes in the balances relate primarily to sales of the Company's genomics services and Neogen Analytics.

The following table summarizes contract liabilities by period:


	Three months ended February 28/29,						Nine months ended February 28/29,
	2025			2024			2025			2024
Beginning balance	$	5,651		$	4,679		$	4,632		$	4,616
Additions		3,021			5,116			10,425			11,094
Recognized into revenue		(2,903	)		(4,309	)		(9,288	)		(10,224	)
Ending balance	$	5,769		$	5,486		$	5,769		$	5,486

The following table presents disaggregated revenue by major product and service categories during the three and nine months ended February 28, 2025 and February 29, 2024


	Three months ended February 28/29,				Nine months ended February 28/29,
	2025		2024		2025		2024
Food Safety
Natural Toxins & Allergens	$	17,595	$	19,738	$	58,479	$	63,116
Bacterial & General Sanitation		39,882		40,395		122,317		128,393
Indicator Testing, Culture Media & Other		77,744		81,168		242,710		246,812
Biosecurity Products		11,815		10,136		35,717		32,180
Genomics Services		5,695		6,317		17,091		17,934
	$	152,731	$	157,754	$	476,314	$	488,435
Animal Safety
Life Sciences	$	1,504	$	1,372	$	4,864	$	4,710
Veterinary Instruments & Disposables		15,412		17,976		45,209		47,845
Animal Care & Other		10,497		10,066		26,951		27,226
Biosecurity Products		23,827		23,055		66,557		65,694
Genomics Services		17,009		18,589		49,307		53,518
		68,249		71,058		192,888		198,993
Total Revenues	$	220,980	$	228,812	$	669,202	$	687,428

3. NET LOSS PER SHARE

Basic net loss per share was computed by dividing net loss by the weighted average number of shares of common stock outstanding during the period. Diluted net loss per share was computed using the treasury stock method by dividing net loss by the weighted average number of shares of common stock outstanding.

The calculation of net loss per share follows:


	Three months ended February 28/29,						Nine months ended February 28/29,
	2025			2024			2025			2024
Numerator for basic and diluted net loss per share:
Net loss attributable to Neogen	$	(10,957	)	$	(2,022	)	$	(479,848	)	$	(4,006	)
Denominator for basic net loss per share:
Weighted average shares		217,031,907			216,597,777			216,845,782			216,438,643
Effect of dilutive stock options and RSUs		—			—			—			—
Denominator for diluted net loss per share		217,031,907			216,597,777			216,845,782			216,438,643
Net loss per share:
Basic	$	(0.05	)	$	(0.01	)	$	(2.21	)	$	(0.02	)
Diluted	$	(0.05	)	$	(0.01	)	$	(2.21	)	$	(0.02	)

Due to the net loss reported for the three and nine months ended February 28, 2025 and the three and nine months ended February 29, 2024, the stock options and RSUs were anti-dilutive.

4. SEGMENT INFORMATION AND GEOGRAPHIC DATA

The Company has two reportable segments: Food Safety and Animal Safety. The Food Safety segment is primarily engaged in the development, production and marketing of diagnostic test kits and related products used by food producers and processors to detect harmful natural toxins, foodborne bacteria, allergens and levels of general sanitation. The Animal Safety segment is primarily engaged in the development, production and marketing of products dedicated to animal safety, including a complete line of consumable products marketed to veterinarians and animal health product distributors. This segment also provides genomic identification and related interpretive bioinformatic services. Additionally, the Animal Safety segment produces and markets biosecurity products to assist in the control of rodents, insects and disease in and around agricultural, food production and other facilities.

Many of our international operations originally focused on the Company’s food safety products, and each of these units reports through the Food Safety segment. In recent years, these operations have expanded to offer the Company’s complete line of products and services, including those usually associated with the Animal Safety segment such as biosecurity products, veterinary instruments and genomics services. These additional products and services are managed and directed by existing management and are reported through the Food Safety segment.

Segment information follows:


	Food Safety		Animal Safety		Corporate and Eliminations (1)			Total
As of and during the three months ended February 28, 2025
Product revenues to external customers	$	145,248	$	51,240	$	—		$	196,488
Service revenues to external customers		7,483		17,009		—			24,492
Total revenues to external customers	$	152,731	$	68,249	$	—		$	220,980
Operating income (loss)	$	19,315	$	6,750	$	(20,650	)	$	5,415
Total assets	$	3,566,450	$	342,181	$	127,705		$	4,036,336

As of and during the three months ended February 29, 2024
Product revenues to external customers	$	149,709	$	52,469	$	—		$	202,178
Service revenues to external customers		8,045		18,589		—			26,634
Total revenues to external customers	$	157,754	$	71,058	$	—		$	228,812
Operating income (loss)	$	15,915	$	14,781	$	(18,673	)	$	12,023
Total assets	$	4,071,831	$	344,205	$	166,456		$	4,582,492

(1)

Includes corporate assets, including cash and cash equivalents, current and deferred tax accounts and overhead expenses not allocated to specific business segments, and excludes intersegment transactions.


	Food Safety			Animal Safety		Corporate and Eliminations (1)			Total
During the nine months ended February 28, 2025
Product revenues to external customers	$	452,974		$	143,581	$	—		$	596,555
Service revenues to external customers		23,340			49,307		—			72,647
Total revenues to external customers	$	476,314		$	192,888	$	—		$	669,202
Operating (loss) income	$	(399,578	)	$	8,977	$	(59,211	)	$	(449,812	)

During the nine months ended February 29, 2024
Product revenues to external customers	$	464,973		$	145,475	$	—		$	610,448
Service revenues to external customers		23,462			53,518		—			76,980
Total revenues to external customers	$	488,435		$	198,993	$	—		$	687,428
Operating income (loss)	$	62,485		$	30,876	$	(47,738	)	$	45,623

(1)

Excludes intersegment transactions.

The following table presents the Company’s revenue disaggregated by geographic location:


	Three months ended February 28/29,				Nine months ended February 28/29,
	2025		2024		2025		2024
Domestic	$	115,365	$	124,226	$	333,509	$	348,848
International		105,615		104,586		335,693		338,580
Total revenue	$	220,980	$	228,812	$	669,202	$	687,428

5. GOODWILL

The following table summarizes goodwill by reportable segment:


	Food Safety			Animal Safety			Total
May 31, 2024	$	2,054,205		$	81,427		$	2,135,632
Impairment		(461,175	)		-			(461,175	)
Foreign currency translation and other		(2,108	)		(644	)		(2,752	)
February 28, 2025	$	1,590,922		$	80,783		$	1,671,705

In the second quarter of fiscal year 2025, the Company identified that the impact of integration challenges and end market conditions on the recent overall financial performance of the Food Safety reporting unit represented a triggering event to test goodwill within that reporting unit for impairment as of September 1, 2024. Management utilized a third-party to quantitatively assess its Food Safety reporting unit. Fair value of the reporting unit was estimated based on a combination of an income-based approach, consisting of a discounted cash flows analysis, and a market-based approach, consisting of pricing multiples derived from an analysis of comparable public companies multiplied against historical and/or anticipated financial metrics of the reporting unit. The inputs to the fair value are defined in the fair value hierarchy as Level 3 inputs. Based on the results of the analysis, the carrying value of the Food Safety reporting unit exceeded its fair value as of September 1, 2024. Accordingly, an impairment charge of $461,390 was recorded. Differences in the balance sheet change and impairment charge are due to foreign exchange.

6. RESTRUCTURING

The Company regularly evaluates its business and objectives to ensure that it is properly configured and sized based on changing market conditions. Accordingly, the Company has implemented certain restructuring initiatives, including consolidation of certain facilities throughout the world and rationalization of its operations. In the second quarter of fiscal year 2025, management initiated a restructuring plan to streamline operations of the Company's global genomics business.

The Company’s restructuring charges consist of severance payments, costs for outplacement services, and post-employment benefits (collectively, “employee separation costs”), other related exit costs and asset impairment charges related to restructuring activities. These amounts are partially recorded within cost of service revenues and partially recorded within general and administrative expense on the condensed consolidated statements of operations.

Restructuring charges by segment were as follows:


	Three months ended February 28/29,					Nine months ended February 28/29,
	2025			2024		2025		2024
Food Safety	$	305		$	131	$	1,941	$	347
Animal Safety		(137	)		199		6,940		1,528
Corporate		—			608		1,225		1,478
Total	$	168		$	938	$	10,106	$	3,353

Restructuring activity for the nine months ended February 28, 2025 was as follows:


	Employee Separation Costs			Other Exit Costs			Total
Balance as of May 31, 2024	$	-		$	-		$	-
Expense		2,420			7,686			10,106
Cash Payments		(1,727	)		(490	)		(2,217	)
Asset impairments and other		-			(7,196	)		(7,196	)
Balance as of February 28, 2025	$	693		$	-		$	693

7. INCOME TAXES

Income tax expense was $1,230 during the three months ended February 28, 2025, and income tax benefit was $22,060 during the nine months ended February 28, 2025. Income tax benefit was $3,800 and $3,900 during the three and nine months ended February 29, 2024. Income tax expense for the quarter is related to changes in the Company’s forecasted pre-tax income using an estimated annualized effective tax rate. The net tax benefit for the nine month period is primarily related to pre-tax losses due to amortization expense and interest expense from the 3M FSD acquisition as well as an income tax benefit of $9,225 associated with goodwill impairment charges. The Organization for Economic Cooperation and Development (“OECD”) Pillar 2 global minimum tax rules, which generally provide for a minimum effective tax rate of 15%, are intended to apply for tax years beginning in 2024. The Company is closely monitoring developments and evaluating the impact these new rules will have on our tax rate, including eligibility to qualify for certain safe harbors. Where no safe harbor is met, the Company has included in its income tax for the three and nine months ended February 28, 2025, a forecasted amount of “top-up” tax for its foreign subsidiaries as required under the applicable rules of the countries that have adopted the Pillar Two directives.

The total amounts of unrecognized tax benefits that, if recognized, would affect the effective tax rate as of February 28, 2025 and May 31, 2024 were $4,336 and $2,739, respectively. Increases in unrecognized tax benefits are primarily associated with the acquired 3M FSD, including positions for transfer pricing and research and development credits.

8. COMMITMENTS AND CONTINGENCIES

The Company is involved in environmental remediation and monitoring activities at its Randolph, Wisconsin manufacturing facility and accrues for related costs, when such costs are determined to be probable and estimable. The Company currently utilizes a pump and treat remediation strategy, which includes semi-annual monitoring and reporting, consulting, and maintenance of monitoring wells. These annual remediation costs are expensed and have ranged from $38 to $131 per year over the past five years. The Company’s estimated remaining liability for these costs is $916 as of both February 28, 2025 and May 31, 2024, measured on an undiscounted basis over an estimated period of 15 years. In fiscal 2019, the Company performed an updated Corrective Measures Study on the site, per a request from the Wisconsin Department of Natural Resources ("WDNR"), and is currently working with the WDNR regarding potential alternative remediation strategies going forward. The Company believes that the current pump and treat strategy is appropriate for the site. In fiscal 2022, in collaboration with the WDNR, the Company initiated an in-situ chemical remediation pilot study, which ran over a two-year period. The results of this study were submitted to the WDNR as part of our standard annual report. If the WDNR were to require a change from the current pump and treat remediation strategy, this change could result in an increase in future costs and, ultimately, an increase in the currently recorded liability, with an offsetting charge to operations in the period recorded. The Company has recorded $100 as a current liability as of February 28, 2025, and the remaining $816 is recorded in other non-current liabilities in the condensed consolidated balance sheets.

In the third quarter of fiscal year 2025, the Company recorded a gain related to a settlement regarding the Company's prior acquisition of certain fixed assets. The amount of $2,700 was received in the third quarter of fiscal year 2025. This amount was partially offset by a related fixed asset impairment of $2,055, which was due to the asset no longer being in use. The amount was recorded within General and administrative on the condensed consolidated statements of operations within the Company's Food Safety operating segment.

Related to the Company's other contingent liabilities, a loss of $1,400 was recorded in the third quarter of fiscal year 2025. This contingency loss was driven by an updated valuation of the performance milestone liability for the Company's CAPInnoVet, Inc. transaction. Finally, in the third quarter of fiscal year 2025, the Company reversed a liability of $930 related to a contingent liability that was recorded as part of the Corvium, Inc. transaction. The final milestone payment was not achieved, resulting in a full reversal of the liability.

In the third quarter of fiscal year 2024, the Company received $1,265 of business interruption insurance proceeds relating to fire damage that occurred in the fourth quarter of fiscal year 2023 at one of our Animal Safety lab facilities. The proceeds were recorded within Cost of Revenues in the condensed consolidated statements of operations.

The Company is subject to certain legal and other proceedings in the normal course of business that, in the opinion of management, are not expected to have a material effect on its future results of operations or financial position.

9. DERIVATIVES AND FAIR VALUE

Derivatives

The Company operates on a global basis and is exposed to the risk that its financial condition, results of operations and cash flows could be adversely affected by changes in foreign currency exchange rates and changes in interest rates. To reduce the potential effects of foreign currency exchange rate movements on net earnings, the Company enters into derivative financial instruments in the form of foreign currency exchange forward contracts with major financial institutions and has also entered into interest rate swap contracts as a hedge against changes in interest rates. The Company has established policies and procedures for risk assessment and the approval, reporting and monitoring of derivative financial instrument activities. On the date the derivative is established, the Company designates the derivative as a cash flow hedge or as an economic hedge in accordance with its established policy. Each reporting period, derivatives are recorded at fair value in other current assets, other assets, accrued liabilities and other long-term liabilities. The change in fair value is recorded in accumulated other comprehensive loss, and amounts are reclassified into earnings on the condensed consolidated statements of operations when transactions are realized. Derivatives that are not determined to be effective hedges are adjusted to fair value with a corresponding adjustment to earnings. The Company does not enter into derivative financial instruments for trading or speculative purposes.

Derivatives Not Designated as Hedging Instruments

The Company forecasts its net exposure in various receivables and payables to fluctuations in the value of various currencies, and has entered into a number of foreign currency forward contracts each month to mitigate that exposure. These contracts are recorded net at fair value on our consolidated balance sheets, classified as Level 2 in the fair value hierarchy. Gains and losses from these contracts are recognized in Other, net in our condensed consolidated statements of operations. The notional amount of forward contracts in place was $80,254 and $70,315 as of February 28, 2025 and May 31, 2024, respectively, and consisted of economic hedges of transactions up to April 2025.



Fair Value of Derivatives Not Designated as Hedging Instruments	Balance Sheet Location	February 28, 2025		May 31, 2024
Foreign currency forward contracts, net	Other current liabilities	$	350	$	265

The location and amount of gains (losses) from derivatives not designated as hedging instruments in our condensed consolidated statements of operations were as follows:


		Three months ended February 28/29,
Derivatives Not Designated as Hedging Instruments	Location in statements of operations	2025			2024
Foreign currency forward contracts	Other, net	$	(57	)	$	150


		Nine months ended February 28/29,
Derivatives Not Designated as Hedging Instruments	Location in statements of operations	2025			2024
Foreign currency forward contracts	Other, net	$	(342	)	$	(391	)

Derivatives Designated as Hedging Instruments

In November 2022, the Company entered into a receive-variable, pay-fixed interest rate swap agreement with a $250,000 notional value, which is designated as a cash flow hedge. In accordance with the agreement, the notional value decreased to $200,000 in November 2024. This agreement fixed a portion of the variable interest due on our term loan facility, with an effective date of December 2, 2022 and a maturity date of June 30, 2027. Under the terms of the agreement, the Company pays a fixed interest rate of 4.215%, plus an applicable margin ranging between 150 to 225 basis points and receive a variable rate of interest based on term SOFR from the counterparty, which is reset according to the duration of the SOFR term. The fair value of the interest rate swap as of February 28, 2025 and May 31, 2024 was a net (liability) asset of ($1,355) and $2,451, respectively. The Company expects to reclassify a $155 loss of accumulated other comprehensive income into earnings in the next 12 months.

We record the fair value of our interest rate swaps on a recurring basis using Level 2 observable market inputs for similar assets or liabilities in active markets.


Fair Value of Derivatives Designated as Hedging Instruments	Balance Sheet Location	February 28, 2025			May 31, 2024
Interest rate swap – current	(Other current liabilities) Prepaid expenses and other current assets	$	(205	)	$	2,222
Interest rate swap – non-current	Other (non-current liabilities) non-current assets	$	(1,150	)	$	229

Fair Value of Financial Instruments

Fair value measurements are determined based upon the exit price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants exclusive of any transaction costs. The Company utilizes a fair value hierarchy based upon the observability of inputs used in valuation techniques as follows:

Level 1: Observable inputs such as quoted prices in active markets;

Level 2: Inputs, other than quoted prices in active markets, that are observable either directly or indirectly; and

Level 3: Unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions.

The carrying amounts of the Company’s financial instruments other than cash equivalents and marketable securities, which include accounts receivable and accounts payable, approximate fair value based on either their short maturity or current terms for similar instruments.

10. ACCUMULATED OTHER COMPREHENSIVE LOSS

Accumulated other comprehensive loss changes by component, net of related tax, were as follows:


	Three months ended February 28/29,						Nine months ended February 28/29,
	2025			2024			2025			2024

Accumulated other comprehensive loss, beginning balance	$	(44,745	)	$	(25,128	)	$	(30,021	)	$	(33,251	)

Foreign currency translation adjustment
Balance at beginning of period	$	(44,002	)	$	(25,607	)	$	(31,885	)	$	(30,285	)
Other comprehensive (loss) gain before reclassifications		(2,658	)		(4,561	)		(14,775	)		117
Balance at end of period	$	(46,660	)	$	(30,168	)	$	(46,660	)	$	(30,168	)

Marketable securities
Balance at beginning of period	$	-		$	(87	)	$	-		$	(927	)
Other comprehensive loss before reclassifications		-			-			-			-
Amounts reclassified from accumulated other comprehensive loss		-			77			-			917
Balance at end of period	$	-		$	(10	)	$	-		$	(10	)

Fair value of derivatives change
Balance at beginning of period	$	(743	)	$	566		$	1,864		$	(2,039	)
Other comprehensive (loss) gain before reclassifications		(170	)		731			(1,797	)		4,439
Amounts reclassified from accumulated other comprehensive loss		(117	)		(592	)		(1,097	)		(1,695	)
Balance at end of period	$	(1,030	)	$	705		$	(1,030	)	$	705

Accumulated other comprehensive loss, ending balance	$	(47,690	)	$	(29,473	)	$	(47,690	)	$	(29,473	)

11. SUBSEQUENT EVENTS

On April 4, 2025, Neogen Food Safety Corporation entered into the Amendment No. 1 and Refinancing Amendment to Credit Agreement (the “Refinancing Amendment”), which amended the existing credit agreement, dated June 30, 2022. The Refinancing Amendment, among other things, provides for (i) a new tranche of senior secured term loans in an aggregate principal amount of $450,000 (the “2025 Term Loans”) and (ii) a revolving credit facility in an aggregate principal amount of $250,000, against which $100,000 has been drawn (the “2025 Revolving Facility”). The 2025 Term Loans will mature on April 4, 2030. The 2025 Revolving Facility will terminate on the earlier of April 4, 2030, or the date on which the revolving commitments under the 2025 Revolving Facility are terminated. The Refinancing Amendment lowered the spread on the term loan and revolver facility borrowings from 2.35% to 1.75% based on a net leverage ratio being greater than 3.0 to 1.0. The other terms and conditions of the loan term agreement remain substantially unchanged.

On April 9, the Company announced that John Adent, the Company’s Chief Executive Officer ("CEO") and President, will be stepping down. Mr. Adent will continue to serve in his existing roles as CEO and President and as a member of the Company’s Board of Directors until his successor has been appointed. Mr. Adent and the Company entered into a CEO transition agreement (the “Transition Agreement”) in connection with the transition of Mr. Adent’s role with the Company. Pursuant to the terms of the Transition Agreement, following the appointment of his successor and until October 31, 2025 (the “Separation Date”), Mr. Adent will continue to be employed by the Company as a Special Advisor to the Board and to the Company’s new CEO.

Pursuant to the terms of the Transition Agreement, Mr. Adent will continue to participate in the Company’s benefit plans and receive his base salary until the Separation Date. Mr. Adent will remain entitled to receive his annual bonus for fiscal year 2025 and will be eligible to earn a pro-rata annual bonus for fiscal year 2026, with any payment amount prorated based on the number of days from the start of the 2026 fiscal year through the Separation Date. Mr. Adent’s outstanding equity incentive awards will be treated in accordance with their terms through the Separation Date. In addition, any stock option awards that are vested as of the Separation Date will remain exercisable for three years following the Separation Date or, if earlier, the full-term expiration of the stock option award. Mr. Adent will not be eligible for any grants of new equity after the date of the Transition Agreement. After the Separation Date, Mr. Adent will receive the severance compensation and benefits provided under and on terms substantially consistent with his current severance letter agreement consistent with a termination without cause; subject to him entering into a release of certain employment claims against the Company as required by the severance letter agreement.

PART I – FINANCIAL INFORMATION

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

The information in this Management’s Discussion and Analysis of Financial Condition and Results of Operations contains both historical financial information and forward-looking statements. Neogen does not provide forecasts of future financial performance. While management is optimistic about the Company’s long-term prospects, historical financial information may not be indicative of future financial results.

Safe Harbor and Forward-Looking Statements

Forward-looking statements, within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, are made throughout this Quarterly Report on Form 10-Q, including statements relating to management’s expectations regarding new product introductions; the adequacy of our sources for certain components, raw materials and finished products; and our ability to utilize certain inventory. For this purpose, any statements contained herein that are not statements of historical fact are deemed to be forward-looking statements. Without limiting the foregoing, the words “believes,” “anticipates,” “plans,” “expects,” “seeks,” “estimates,” and similar expressions are intended to identify forward-looking statements. These forward-looking statements are intended to provide our current expectations or forecasts of future events; are based on current estimates, projections, beliefs, and assumptions; and are not guarantees of future performance. Actual events or results may differ materially from those described in the forward-looking statements. There are a number of important factors that could cause Neogen’s results to differ materially from those indicated by such forward-looking statements, including many factors beyond our control. Factors that could cause actual results to differ from those contained within forward-looking statements include (without limitation) the continued integration of the 3M food safety business and the realization of the expected benefits from that acquisition; the relationship with and performance of our transition manufacturing partner; our ability to adequately and timely remediate certain identified material weaknesses in our internal control over financial reporting; competition; recruitment and retention of key employees; impact of weather on agriculture and food production; global business disruption caused by the Russia invasion in Ukraine and related sanctions and the conflict in the Middle East; identification and integration of acquisitions; research and development risks; intellectual property protection; increasing and developing government regulation; and other risks detailed from time to time in the Company’s reports on file at the Securities and Exchange Commission, including this Quarterly Report on Form 10-Q.

In addition, any forward-looking statements represent management’s views only as of the date this Quarterly Report on Form 10-Q was first filed with the Securities and Exchange Commission and should not be relied upon as representing management’s views as of any subsequent date. Except to the extent legally required to do so, the Company specifically disclaims any obligation to update forward-looking statements, even if its views change.

Trends and Uncertainties

In prior years, production was negatively impacted by broad supply chain challenges and labor market disruptions. Additionally, input cost inflation, including increases in certain raw materials, negatively impacted operating results. In fiscal year 2024, despite a slowing rate of inflation, there were economic headwinds of softening consumer demand and higher interest rates, coupled with ongoing geopolitical tension in certain regions.

Interest rates have risen sharply, particularly in fiscal year 2023, as a way to combat inflation. This increased our borrowing costs and raised the overall cost of capital. Although the federal funds rate was reduced in 2024 and there are indications of future rate cuts, the overall interest rate we pay on our Credit Facilities remains higher than when the debt was incurred in 2022, which increases interest expense on the unhedged portion of our Term Loan. In response to the historically high inflationary environment, we took pricing actions to mitigate the impacts on the business in the prior two fiscal years. The impact of inflation continues to affect us in the current fiscal year, although at a lower rate compared to prior fiscal years.

Beginning in the first half of fiscal year 2024, we implemented a new enterprise resource planning system and exited our transition distribution agreements with 3M, which led to certain shipment delays and an elevated backlog of open orders, specifically in the Food Safety segment. At the conclusion of fiscal year 2024, order fulfillment issues were largely resolved, however, the impact of lost market share stemming from these fulfillment issues has continued in fiscal year 2025. Also in fiscal year 2025, we have experienced negative impacts from delays in restarting full production of our sample collection product line, which we relocated from 3M into a Neogen facility. However, at the end of the third quarter of this fiscal year, we resolved these delays, with production having

returned to the prior normal levels. With a change in administration in fiscal year 2025, there has been an economic policy shift towards increasing tariffs, which in turn has led and could lead to further retaliatory tariffs. These have the potential to negatively impact our international sales, as the majority of our purchases and production is done within the U.S.

Although we have no operations in or direct exposure to Russia, Belarus or Ukraine, we have experienced intermittent shortages in materials and increased costs for transportation, energy and raw materials due, in part, to the negative impact of the Russia-Ukraine military conflict, which began in February 2022, on the global economy. Our European operations and customer base have been negatively impacted by the conflict. Similarly, the military conflicts in the Middle East have increased overall geopolitical tensions. As the respective conflicts continue or worsen, they may further impact our business, financial condition or results of operations throughout fiscal year 2025.

Within the Food Safety industry, the end market continues to have a lower level of food production, partly due to significant inflation in food prices. However, there has generally been gradual end market improvement that has coincided with an increasing focus on food safety from both consumers and regulators. Within Animal Safety, the end market is at or near cyclical lows. As a result, we are optimistic about future revenue growth in the segment, particularly if the distribution channel begins to meaningfully restock inventory.

The restructuring actions undertaken in our genomics business have resulted in the voluntary attrition of revenue, following the shift in focus already made away from smaller production animals. A portion of our genomics business also serves the companion animal market, which has been experiencing weakness recently, primarily due to the impact of continued inflation, a lower number of pet adoptions, and a higher level of customer in-sourcing.

We continue to evaluate the nature and extent to which these issues impact our business, including consolidated results of operations, financial condition and liquidity. We expect these issues to continue to impact us throughout the remainder of fiscal year 2025.

Critical Accounting Estimates

During the second quarter of fiscal year 2025, we incurred a goodwill impairment charge of $461.4 million associated with our Food Safety reporting unit. Subsequent to the goodwill impairment charge, the fair value of this reporting unit approximated its carrying value. The fair value of the reporting unit is estimated based on a combination of an income approach, which utilizes discounted cash flows and a market approach, which utilizes pricing multiples derived from an analysis of comparable public companies multiplied against historical and/or anticipated financial metrics of the reporting unit. The rate used to discount the cash flows under the income approach was 10.0%. These calculations contain uncertainties as they require management to make assumptions including, but not limited to, market comparables, future cash flows of the reporting unit, and appropriate discount and long-term growth rates.

A decline in the actual cash flows of the Food Safety reporting unit in future periods, as compared to the projected cash flows used in the valuation, could result in the carrying value of this reporting unit exceeding its fair value. Further, a change in market comparables, discount rate or long-term growth rate, as a result of a change in economic conditions or otherwise could result in the carrying value of this reporting unit exceeding its fair value, which would result in an additional impairment charge.

Our critical accounting estimates are included in our Annual Report on Form 10-K for the year ended May 31, 2024 and did not materially change during the three months ended February 28, 2025.

Executive Overview


	Three months ended February 28/29,									Nine months ended February 28/29,
	2025			2024			Increase / (Decrease)			2025			2024			Increase / (Decrease)
Total Revenues	$	220,980		$	228,812		$	(7,832	)	$	669,202		$	687,428		$	(18,226	)
Cost of Revenues		110,715			111,929			(1,214	)		340,681			337,010			3,671
Gross Profit		110,265			116,883			(6,618	)		328,521			350,418			(21,897	)
Operating Expenses
Sales and marketing		44,595			47,920			(3,325	)		136,939			138,535			(1,596	)
General and administrative		55,782			52,087			3,695			165,224			148,929			16,295
Goodwill impairment		—			—			—			461,390			—			461,390
Research and development		4,473			4,853			(380	)		14,780			17,331			(2,551	)
Total Operating Expenses		104,850			104,860			(10	)		778,333			304,795			473,538
Operating Income (Loss)		5,415			12,023			(6,608	)		(449,812	)		45,623			(495,435	)
Other Expense
Interest income		699			1,612			(913	)		2,466			5,265			(2,799	)
Interest expense		(17,737	)		(18,285	)		548			(54,493	)		(54,773	)		280
Other expense, net		1,896			(1,172	)		3,068			(69	)		(4,021	)		3,952
Total Other Expense		(15,142	)		(17,845	)		2,703			(52,096	)		(53,529	)		1,433
Loss Before Taxes		(9,727	)		(5,822	)		(3,905	)		(501,908	)		(7,906	)		(494,002	)
Income Tax Expense (Benefit)		1,230			(3,800	)		5,030			(22,060	)		(3,900	)		(18,160	)
Net Loss	$	(10,957	)	$	(2,022	)	$	(8,935	)	$	(479,848	)	$	(4,006	)	$	(475,842	)

Results of Operations

Revenues

Revenue decreased $7.8 million during the three months ended February 28, 2025 compared to the three months ended February 29, 2024. The decrease included a $7.1 million unfavorable foreign exchange rate impact and a $1.2 million unfavorable impact due to discontinued product lines, offset by $0.5 million of growth in the business. The increase in the business was driven by new sales in the food quality and nutritional analysis product line paired with continued strength in indicator testing and pathogens product lines. These were partially offset by reduced sales of sample collection products due to production constraints, lower genomics volume due primarily to weakness in the companion animal market and a decline in sales of veterinary instruments, which have been impacted by tariffs.

Revenue decreased $18.2 million during the nine months ended February 28, 2025 compared to the nine months ended February 29, 2024. The decrease included a $21.9 million unfavorable foreign exchange rate impact and a $1.8 million unfavorable impact due to discontinued product lines, offset by $5.5 million of growth in the business. The year-to-date increase was driven by continued strength in indicator testing paired with new sales in the food quality and nutritional analysis product line. These increases were partially offset by production constraints within the sample collection product line and lower genomics volume, which was impacted by a shift to focus on large production animals and weakness in the companion animal market.

Service Revenue

Service revenue, which consists primarily of genomics services provided to animal production and companion animal markets, was $24.5 million and $72.6 million during the three and nine months ended February 28, 2025 and $26.6 million and $77.0 million during the three and nine months ended February 29, 2024, respectively. The decrease in the three and nine months ended February 28, 2025 was primarily due to lower genomics sales into the companion animal market, as well as lower sales into the domestic poultry market, primarily due to a shift in focus towards large production animals, offset by an increase in genomics sales into beef markets.

International Revenue

International sales were $105.6 million and $335.7 million during the three and nine months ended February 28, 2025 and $104.6 million and $338.6 million during the three and nine months ended February 29, 2024, respectively. The increase during the three months ended February 28, 2025 was driven by increases in the Latin American countries, partially offset by a $7.1 million currency headwind and decreases in the Europe region. The decrease during the nine months ended February 28, 2025 was due to $21.9 million of currency headwinds, partially offset by an increase in the Latin American countries and to a lesser extent, countries within Asia Pacific and Europe.

Gross Margin

Gross margin was 49.9% and 49.1% during the three and nine months ended February 28, 2025 and 51.1% and 51.0% during the three and nine months ended February 29, 2024, respectively. The decrease in margin during the three month period was primarily due to lower volume and higher manufacturing costs related to our sample collection product line. The decrease in margin during the nine month period was primarily due to higher freight costs in the current year and $4.6 million of restructuring charges. Additionally, a sales decline in the first and third quarters contributed to lower gross margin for the year-to-date period.

Operating Expenses

Sales and Marketing

Sales and marketing expenses were $44.6 million and $136.9 million during the three and nine months ended February 28, 2025 and $47.9 million and $138.5 million during the three and nine months ended February 29, 2024, respectively. While we experienced higher shipping costs in the current year, as we took over distribution of FSD products from 3M during the second and third quarters of the prior fiscal year, these increased costs were more than offset by a decrease in fees paid to 3M for distribution services and lower royalty expense.

General and Administrative

General and administrative expenses were $55.8 million and $165.2 million during the three and nine months ended February 28, 2025 and $52.1 million and $148.9 million during the three and nine months ended February 29, 2024, respectively. For the Food Safety segment, increases compared to the prior year comparable periods were driven by a fixed asset impairment charge of $2.1 million. For the Animal Safety segment, an increase in expense for the full year was attributable to restructuring charges, which included $6.9 million of charges that were primarily incurred in the second quarter of the current fiscal year. Corporate expense has increased primarily due to additional headcount and higher costs associated with our prior year enterprise resource planning system implementation.

General and administrative expenses include amortization expense relating to definite-lived intangible assets of $23.3 million and $70.4 million during the three and nine months ended February 28, 2025 and $23.7 million and $71.1 million during the three and nine months ended February 29, 2024, respectively. Estimated amortization expense for fiscal years 2025 through 2029 is expected to be in the range of approximately $90 million to $96 million per year.

Goodwill Impairment

During the nine months ended February 28, 2025, goodwill impairment charges were $461.4 million. There were no goodwill impairment charges recorded during the prior year comparable period.

Research and Development

Research and development expense was $4.5 million and $14.8 million during the three and nine months ended February 28, 2025 and $4.9 million and $17.3 million during the three and nine months ended February 29, 2024, respectively. The decrease during the three and nine months ended February 28, 2025 is primarily the result of lower contracted services and employee costs in the Food Safety segment, as we continue to realize synergies in certain areas from the 3M FSD business.

Other Expense

Other expense was $15.1 million and $52.1 million during the three months ended February 28, 2025 and $17.8 million and $53.5 million during the three and nine months ended February 29, 2024, respectively. The decrease in expense during both comparable periods was due to a gain related to a settlement regarding the Company's prior acquisition of certain fixed assets. The decrease in expense was also driven by lower interest expense during both comparable periods. The lower interest expense was a result of our interest rate swap instrument. These favorable impacts were partially offset by a reduction in interest income associated with our money market portfolio.

Provision for Income Taxes

Income tax expense was $1.2 million during the three months ended February 28, 2025 and income tax benefit was $22.1 million during the nine months ended February 28, 2025 compared to income tax benefit of $3.8 million and $3.9 million during the three and nine months ended February 29, 2024. Income tax expense for the quarter is related to changes in the Company’s forecasted pre-tax income using an estimated annualized effective tax rate. The net tax benefit for the nine month period is primarily related to pre-tax losses due to amortization expense and interest expense from the 3M FSD acquisition as well as an income tax benefit of $9.2 million associated with goodwill impairment charges. The Organization for Economic Cooperation and Development (“OECD”) Pillar 2 global minimum tax rules, which generally provide for a minimum effective tax rate of 15%, are intended to apply for tax years beginning in 2024. We are closely monitoring developments and evaluating the impact these new rules will have on our tax rate, including eligibility to qualify for certain safe harbors. Where no safe harbor is met, we have included in our income tax for the three and nine months ended February 28, 2025, a forecasted amount of “top-up” tax for our foreign subsidiaries as required under the applicable rules of the countries that have adopted the Pillar Two directives.

Segment Results of Operations


	Three months ended February 28/29,
	2025			2024			Increase / (Decrease)			% Change
Food Safety	$	152,731		$	157,754		$	(5,023	)		(3	)%
Animal Safety		68,249			71,058			(2,809	)		(4	)%
Total Revenues	$	220,980		$	228,812		$	(7,832	)		(3	)%

Food Safety	$	19,315		$	15,915		$	3,400			21	%
Animal Safety		6,750			14,781			(8,031	)		(54	)%
Segment Operating Income	$	26,065		$	30,696		$	(4,631	)		(15	)%
Corporate		(20,650	)		(18,673	)		(1,977	)		11	%
Operating Income	$	5,415		$	12,023		$	(6,608	)		(55	)%


	Nine months ended February 28/29,
	2025			2024			Increase / (Decrease)			% Change
Food Safety	$	476,314		$	488,435		$	(12,121	)		(2	)%
Animal Safety		192,888			198,993			(6,105	)		(3	)%
Total Revenues	$	669,202		$	687,428		$	(18,226	)		(3	)%

Food Safety	$	(399,578	)	$	62,485		$	(462,063	)		(739	)%
Animal Safety		8,977			30,876			(21,899	)		(71	)%
Segment Operating (Loss) Income	$	(390,601	)	$	93,361		$	(483,962	)		(518	)%
Corporate		(59,211	)		(47,738	)		(11,473	)		24	%
Operating (Loss) Income	$	(449,812	)	$	45,623		$	(495,435	)		(1086	)%

Revenues

Revenue for the Food Safety segment decreased $5.0 million during the three months ended February 28, 2025 compared to the three months ended February 29, 2024. The decrease was primarily due to $6.9 million of currency headwind and $0.5 million from discontinued product lines, partially offset by $2.4 million of growth in the business. The increase in the business was driven by new sales in the food quality and nutritional analysis product line and strong sales in the indicator and pathogens product lines. These increases were partially offset by lower sales from the sample collection product line due to production constraints and lower sales in the culture media and general sanitation product lines.

Revenue for the Food Safety segment decreased $12.1 million during the nine months ended February 28, 2025 compared to the nine months ended February 29, 2024. The decrease was primarily due to $21.8 million of currency headwind and $0.5 million from discontinued product lines, partially offset by $10.2 million of growth in the business. The growth was driven by continued strength in indicator testing, new sales in the food quality and nutritional analysis product line and higher sales of cleaner and disinfectant products in the Europe and Latin America regions. These increases were partially offset by production constraints impacting the sample collection product line and lower sales in the natural toxins product line.

Revenue for the Animal Safety segment decreased $2.8 million during the three months ended February 28, 2025 compared to the three months ended February 29, 2024. The decrease was due to a $1.8 million decrease in the business, a $0.7 million impact from discontinued product lines and a $0.3 million unfavorable currency impact. The decline in the business was primarily related to decreased sales of veterinary instruments, which have been impacted by tariffs, and lower genomics volume, due primarily to weakness in the companion animal market. These decreases were partly offset by continued strength in rodent control products.

Revenue for the Animal Safety segment decreased $6.1 million during the nine months ended February 28, 2025 compared to the nine months ended February 29, 2024. The decrease was primarily due to a $4.7 million decline in the business, a $1.3 million impact from discontinued product lines and a $0.1 million unfavorable currency impact. The decline in the business was driven by lower genomics volume due to a shift to focus primarily on large production animals and weakness in the companion animal market paired with lower sales in the insect control and veterinary instruments product lines. These decreases were partially offset by strength in rodent control products.

Operating Income

Operating income for the Food Safety segment increased $3.4 million during the three months ended February 28, 2025 compared to the three months ended February 29, 2024. While revenues decreased on a quarter-to-date basis, these decreases were offset by a higher gross margin and reduced operating expenses, partially due to restructuring activities that were incurred in the second quarter of the current fiscal year.

Operating income for the Food Safety segment decreased $462.1 million during the nine months ended February 28, 2025 compared to the nine months ended February 29, 2024. The decline was primarily due to the impairment charges of $461.4 million in the second quarter of fiscal 2025.

Operating income for the Animal Safety segment decreased $8.0 million during the three months ended February 28, 2025 compared to the three months ended February 29, 2024. The decline was due to both decreased sales and a reduced gross margin, as certain overhead charges increased during the quarter.

Operating income for the Animal Safety segment decreased $21.9 million during the nine months ended February 28, 2025 compared to the nine months ended February 29, 2024. The decline was due to a decrease in sales and restructuring charges incurred primarily in the second quarter of the current fiscal year, which impacted both gross profit and operating expenses.

The increased corporate expense during each comparable period related to headcount increases, increases in equity-based compensation and costs associated with our new enterprise resource planning system.

Non-GAAP Financial Measures

This report includes certain financial information for the Company that differs from what is reported in accordance with U.S. GAAP. These non-GAAP financial measures consist of EBITDA, Adjusted EBITDA, and Adjusted EBITDA margin. These non-GAAP financial measures are included in this report because management believes that they provide investors with additional useful information to measure the performance of the Company, and because these non-GAAP financial measures are frequently used by securities analysts, investors and other interested parties as common performance measures to compare results or estimate valuations across companies in industries the Company operates in. The Company also uses Adjusted EBITDA as a performance target to establish and award certain executive compensation awards, as disclosed in our proxy statement filed with the Securities and Exchange Commission on September 13, 2024.

EBITDA

We define EBITDA as net income before interest, income taxes, and depreciation and amortization. We present EBITDA as a performance measure because it may allow for a comparison of results across periods and results across companies in the industries in which Neogen operates on a consistent basis, by removing the effects on operating performance of (a) capital structure (such as the varying levels of interest expense and interest income), (b) asset base and capital investment cycle (such as depreciation and amortization) and (c) items largely outside the control of management (such as income taxes). EBITDA also forms the basis for the measurement of Adjusted EBITDA (discussed below).

Adjusted EBITDA

We define Adjusted EBITDA as EBITDA, adjusted for share-based compensation and certain other fees and expenses. We present Adjusted EBITDA because it provides an understanding of underlying business performance by excluding the following:

•

Share-based compensation

•

FX translation (gain)/loss on loan revaluation and other revaluation

•

Certain transaction fees and integration costs

•

Restructuring

•

Goodwill impairment

•

Contingent consideration adjustments

•

ERP expense

•

Other income and expense items that do not recur on a frequent or regular basis

Adjusted EBITDA margin

We define Adjusted EBITDA margin as Adjusted EBITDA as a percentage of total revenues. We present Adjusted EBITDA margin as a performance measure to analyze the level of Adjusted EBITDA generated from total revenue.

These non-GAAP financial measures are presented for informational purposes only. EBITDA, Adjusted EBITDA and Adjusted EBITDA margin are not recognized terms under GAAP and should not be considered in isolation or as a substitute for, or superior to, net (loss) income, operating income, cash flow from operating activities or other measures of financial performance. This information does not purport to represent the results Neogen would have achieved had any of the transactions for which an adjustment is made occurred at the beginning of the periods presented or as of the dates indicated. This information is inherently subject to risks and uncertainties. It may not give an accurate or complete picture of Neogen’s financial condition or results of operations for the periods presented and should not be relied upon when making an investment decision.

The use of the terms EBITDA, Adjusted EBITDA, and Adjusted EBITDA margin may not be comparable to similarly titled measures used by other companies or persons due to potential differences in the method of calculation.

These non-GAAP financial measures have limitations as analytical tools. For example, for EBITDA-based metrics:

•

they do not reflect changes in, or cash requirements for, Neogen’s working capital needs;

•

they do not reflect Neogen’s tax expense or the cash requirements to pay taxes;

•

they do not reflect the historical cash expenditures or future requirements for capital expenditures or contractual commitments;

•

they do not reflect any cash requirements for future replacements of assets that are being depreciated and amortized; and

•

they may be calculated differently from other companies in Neogen’s industries limiting their usefulness as comparative measures.

A reader should compensate for these limitations by relying primarily on the financial statements of Neogen and using these non-GAAP financial measures only as a supplement to evaluate Neogen’s performance.

For each of these non-GAAP financial measures below, we are providing a reconciliation of the differences between the non-GAAP measure and the most directly comparable GAAP measure.

Reconciliation between net loss and EBITDA and Adjusted EBITDA and between net loss margin % and Adjusted EBITDA margin % are as follows:


	Three months ended February 28/29,						Nine months ended February 28/29,
	2025			2024			2025			2024
Net loss	$	(10,957	)	$	(2,022	)	$	(479,848	)	$	(4,006	)
Net loss margin %		-5.0	%		-0.9	%		-71.7	%		-0.6	%
Income tax expense (benefit)		1,230			(3,800	)		(22,060	)		(3,900	)
Depreciation and amortization		29,373			29,650			89,222			87,853
Interest expense, net		17,038			16,673			52,027			49,508
EBITDA	$	36,684		$	40,501		$	(360,659	)	$	129,455
Share-based compensation		4,160			3,679			12,961			9,829
FX transaction (gain) loss on loan and other revaluation (1)		(255	)		638			(191	)		1,350
Transaction costs (2)		518			1,103			1,636			2,360
3M integration costs (3)		662			3,807			5,450			8,930
Sample collection transition and ramp up costs (4)		2,843			541			4,676			800
Petrifilm duplicate startup costs (5)		645			—			794			—
Transformation initiatives and related costs (6)		2,438			—			3,265			—
Restructuring (7)		168			938			10,106			3,353
Goodwill impairment		—			—			461,390			—
Contingent consideration adjustments		470			(200	)		470			250
ERP expense (8)		633			1,701			3,184			3,904
Other		(453	)		33			526			(21	)
Adjusted EBITDA	$	48,513		$	52,741		$	143,608		$	160,210
Adjusted EBITDA margin %		22.0	%		23.0	%		21.5	%		23.3	%

(1)

Net foreign currency transaction (gain) loss associated with the revaluation of foreign denominated intercompany loans and certain 3M agreements.

(2)

Includes legal, accounting, tax and other related consulting costs associated with corporate transactions and capital structure initiatives.

(3)

Includes costs associated with 3M transition agreements and related integration costs.

(4)

Includes costs associated with the transitioning of the 3M transition contract manufacturing agreement and ramp up costs associated with our sample collection product line.

(5)

Duplicate costs associated with the startup of Petrifilm manufacturing.

(6)

Includes consulting and other costs, including severance, associated with transformation initiatives.

(7)

Severance, non-cash impairment, and other related exit costs primarily associated with a reduction in our global genomics business and consolidation of certain facilities.

(8)

Expenses related to ERP implementation.

Adjusted EBITDA decreased $4.2 million and $16.6 million during the three and nine months ended February 28, 2025. Expressed as a percentage of revenue, Adjusted EBITDA was 22.0% and 21.5% during the three and nine months ended February 28, 2025 and 23.0% and 23.3% during the three and nine months ended February 29, 2024 2024, respectively. The lower Adjusted EBITDA in the current year was driven primarily by lower sales and higher operating expenses compared to the prior year period.

Financial Condition and Liquidity

Our primary sources of liquidity are cash and cash equivalents, cash flows from the operations of our business, and available borrowing capacity under our revolving facility. Our principal uses of cash include working capital-related items, capital expenditures, debt service, and strategic investments.


Large accelerated filer	☒	Accelerated filer	☐
Non-accelerated filer	☐	Smaller Reporting Company	☐
Emerging growth company	☐


		Page No.
PART I. FINANCIAL INFORMATION

Item 1.	Interim Condensed Consolidated Financial Statements (unaudited)	2
	Condensed Consolidated Balance Sheets – February 28, 2025 and May 31, 2024	2
	Condensed Consolidated Statements of Operations – Three and nine months ended February 28, 2025 and February 29, 2024	3
	Condensed Consolidated Statements of Comprehensive (Loss) Income – Three and nine months ended February 28, 2025 and February 29, 2024	4
	Condensed Consolidated Statements of Equity – Three and nine months ended February 28, 2025 and February 29, 2024	5
	Condensed Consolidated Statements of Cash Flows – Nine months ended February 28, 2025 and February 29, 2024	6
	Notes to Interim Condensed Consolidated Financial Statements – February 28, 2025	7
Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	18
Item 3.	Quantitative and Qualitative Disclosures About Market Risk	30
Item 4.	Controls and Procedures	31

PART II. OTHER INFORMATION

Item 1.	Legal Proceedings	32
Item 1A.	Risk Factors	32
Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	32
Item 5.	Other Information	32
Item 6.	Exhibits	33

SIGNATURES		34

	CEO Certification

	CFO Certification

	Section 906 Certification




31.1	Certification of Principal Executive Officer


31.2	Certification of Chief Financial Officer

32	Certification Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

101.INS	Inline XBRL Instance Document – the instance document does not appear in the Interactive Data File as its XBRL tags are embedded within the Inline XBRL document

101.SCH	Inline XBRL Taxonomy Extension Schema Document

101.CAL	Inline XBRL Taxonomy Extension Calculation Linkbase Document

101.DEF	Inline XBRL Taxonomy Extension Definition Linkbase Document

101.LAB	Inline XBRL Taxonomy Extension Label Linkbase Document

101.PRE	Inline XBRL Taxonomy Extension Presentation Linkbase Document

104	Cover Page Interactive Data File (formatted as inline XBRL and contained in Exhibit 101)


Period	Shares Purchased		Average Price Paid per Share		Shares Purchased as Part of Publicly Announced Plans or Programs		Maximum Number of Shares That May Yet Be Purchased Under the Plans or Programs
December 2024		—		—		—		5,900,000
January 2025		—		—		—		5,900,000
February 2025		—		—		—		5,900,000
Total		—		—		—		5,900,000